DONNA

TapImmune Launches Trial

January 23rd, 2017 | Posted In: Donna Blog, Front Page Feature, Research Updates

TapImmune Launches Phase 2 Ovarian Cancer
Trial In Platinum-Sensitive Patients

Company-Sponsored Ovarian Cancer Trial
Has FDA Fast Track Designation

 

TapImmune, Inc. (NASDAQ: TPIV), a clinical- stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer and metastatic disease today announced the opening of its Phase 2 company-sponsored ovarian cancer study in platinum-sensitive ovarian cancer patients. The company’s first three clinical sites have received regulatory and Investigational Review Board (IRB) approval to begin enrollment. The study will utilize TPIV 200, a T-cell therapy targeting the folate receptor alpha protein.
Read More »

Leave a Reply

Be the First to Comment!

Notify of
wpDiscuz

Stay Posted

Stay Posted

Locals Rule

Locals Rule

YesWay

YesWay

Team Donna

Team Donna

Donna partners

The Donna Foundation

The Donna Foundation

Jeff Galloway

Jeff Galloway

Mayo Clinic

Mayo Clinic

Learn More

First Coast News